Enhanced ER coregulator’s interactions via an acetylation-dependent activation of ERα have potential implications in breast cancers, e.g., SRC-3/AIB1 gene amplifications and ERα gain-of-function mutations in endocrine-resistant metastatic tumors, such as Y537S and D538G [154]. The gene discussed is ESR1; the disease is breast carcinoma.